2 completed, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow DalCor Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS Dalcetrapib, Placebo - Acute Coronary Syndrome | Phase 3 | Recruiting | DalCor Pharmaceuticals | 2000 | 2023-10-03 | 2026-06-22 |
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 Dalcetrapib, Placebo - Covid19 | Phase 2 | Completed | DalCor Pharmaceuticals | 227 | 2021-01-11 | 2022-12-07 |
| Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS dalcetrapib, Placebo - Acute Coronary Syndrome | Phase 3 | Completed | DalCor Pharmaceuticals | 6147 | 2016-04-01 | 2022-10-12 |
Acute Coronary Syndrome (2) · COVID-19 (1)
dalcetrapib (3)
Canada (3) · Puerto Rico (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1)
David Kallend (1) · David Kallend, MBBS (1) · Donald M Black, MD (1)